Posted by Michael Wonder on 02 Feb 2025
US FDA approves Celltrion's Avtozma (tocilizumab-anoh), a biosimilar to Actemra
30 January 2025 - Approval was received for multiple indications, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.
Celltrion today announced that the US FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous and subcutaneous formulation as a biosimilar to Actemra.
